更新于：2024-07-01
Oxycodone
羟考酮
更新于：2024-07-01
概要
基本信息
简介Oxycodone是一种阿片类止痛药物，有时也被称为麻醉剂。它是一种通过结合大脑和脊髓中的μ、κ和δ受体来缓解疼痛的阿片类药物。Oxycodone的化学名称为4,5 α-环氧-14-羟基-3-甲氧基-17-甲基吗啡酮-6-酮。该药物在美国和中国获得批准，并由Collegium制药公司生产。Oxycodone是一种高效的止痛药物，常用于管理中度到重度疼痛，如癌症、手术或创伤引起的疼痛。然而，由于其成瘾和滥用的潜在风险，它被列为受控物质，只能在医疗专业人士的指导下使用。 |
药物类型 小分子化药 |
别名 (-)-14-Hydroxydihydrocodeinone、4,5-Epoxy-14-hydroxy-3-methoxy-17-methylmorphinan-6-one、4,5alpha-Epoxy-14-hydroxy-3-methoxy-17-methylmorphinan-6-one + [21] |
作用机制 Opioid receptors激动剂(阿片样受体激动剂) |
最高研发阶段批准上市 |
首次获批日期 中国 (2004-01-21), |
最高研发阶段(中国)批准上市 |
特殊审评突破性疗法 (美国)、快速通道 (美国) |
登录后查看首次获批时间轴
结构
分子式C18H21NO4 |
InChIKeyBRUQQQPBMZOVGD-XFKAJCMBSA-N |
CAS号76-42-6 |
关联
406
项与 羟考酮 相关的临床试验Application of remimazolam combined with oxycodone in elderly patients with hypertension undergoing colon polypectomy
Optimal Multimodal Pain Management Package Versus Regular Bottled Pain Formulation for Outpatient Use Following Microdiscectomies , Foraminotomies, and Spinal Decompressions: A Randomized Control Trial Comparing Two Strategies
Standard vs. Lower Pressure Pneumoperitoneum in Laparoscopic Gynecologic Surgery: A Randomized Controlled Trial
100 项与 羟考酮 相关的临床结果
登录后查看更多信息
100 项与 羟考酮 相关的转化医学
登录后查看更多信息
100 项与 羟考酮 相关的专利（医药）
登录后查看更多信息
4,635
项与 羟考酮 相关的文献（医药）2024-12-31Annals of medicine
Opioids in geriatric units in 14 Belgian hospitals: prevalence, dosage and associated factors
Article
作者: Delaere, Jozefien ; Van Den Noortgate, Nele J ; Werbrouck, Bart ; Van Puyvelde, Katrien ; Piers, Ruth D ; Van Mulders, Katlijn ; Mouton, Veerle ; Maere, Caroline ; Desmet, Peter ; De Raes, Eva ; Kympers, Celine ; Steen, Elke ; Janssens, Wim Henri ; Dekoninck, Julien
Introduction: Adverse effects of opioids are common among older individuals, and undertreatment as well as overuse can be an issue. Epidemiological data on opioid use in older individuals are available, but scarce in hospitalized patients.Aims: The aim of this study is to examine the one-day prevalence of opioid use among older inpatients and identify the factors associated with both opioid use and dosage.Materials and methods: One-day cross-sectional study with data collected from geriatric units across 14 Belgian hospitals. The primary focus of the study is to assess the prevalence of opioid use and dosage, along with identifying associated factors. To achieve this, a multiple binary logistic regression model was fitted for opioid use, and a multiple linear regression model for opioid dose.Results: Opioids were used in 24.4% of 784 patients, of which 57.9% was treated with tramadol, 13.2% with oxycodone or morphine and 28.9% with transdermal buprenorphine or fentanyl. The odds for opioid use were 4.2 times higher in patients in orthogeriatric units compared to other patients (OR=4.2, 95% CI=2.50-7.05). The prevalence of opioid use was 34% higher in patients without dementia compared to patients with dementia (OR=0.66, 95% CI=0.46-0.95). The overall mean daily dosage was 14.07mg subcutaneous morphine equivalent. After adjustment for age, gender and dementia, dosage was only associated with type of opioid: the estimated mean opioid dose was 70% lower with tramadol (mean ratio=0,30,95% CI=0,23-0,39) and 67% lower with oxycodone and morphine (mean ratio=0,33, 95% CI=0,22-0,48) compared to transdermal buprenorphine and transdermal fentanyl.Conclusions: One in four patients received opioid treatment. It is not clear whether this reflects under- or overtreatment, but these results can serve as a benchmark for geriatric units to guide future pain management practices. The utilization of transdermal fentanyl and buprenorphine, resulting in higher doses of morphine equivalent, poses significant risks for side effects.
2024-04-01American journal of obstetrics and gynecology
A personalized protocol for prescribing opioids after cesarean delivery: leveraging the electronic medical record to reduce outpatient opioid prescriptions
Article
作者: Nelson, David B ; Imo, Chinonye S ; McIntire, Donald D ; McGuire, Jennifer ; Duryea, Elaine L ; Macias, Devin A
BACKGROUND:
Although cesarean delivery is the most common surgery performed in the United States, prescribing practices for analgesia vary. Strategies to manage postpartum pain have mostly focused on the immediate postpartum period when patients are still admitted to the hospital. At discharge, most providers prescribe a fixed number of opioid tablets. Most patients do not use all the opioids that they are prescribed at hospital discharge. This leads to an excess of opioids in the community, which can ultimately lead to misuse and diversion.
OBJECTIVE:
This study aimed to determine whether a transition from universal opioid prescribing to a personalized, patient-specific protocol decreases morphine milligram equivalents prescribed at hospital discharge after cesarean delivery while adequately controlling pain.
STUDY DESIGN:
This was a prospective cohort study of patients undergoing cesarean delivery before and after the implementation of a personalized opioid-prescribing practice at the time of hospital discharge. Each patient was prescribed scheduled ibuprofen and acetaminophen, with a prescription for oxycodone tablets equal to 5 times the morphine milligram equivalents used in the 24 hours before discharge, calculated via an electronic order set. The previous traditional cohorts were routinely prescribed 30 tablets of acetaminophen-codeine 300/30 mg. The primary outcome was morphine milligram equivalents prescribed at discharge. A hotline to address pain control issues after discharge was established, and calls, emergency department visits, and readmissions were examined. Statistical analyses was performed using chi-square and Wilcoxon rank-sum test, with a P value of <.05 considered statistically significant.
RESULTS:
Overall, 412 patients underwent cesarean delivery in the 6 weeks after initiation of the personalized prescribing protocol and were compared with 367 patients before the change. The median morphine milligram equivalents prescribed at discharge was lower with personalized prescribing (37.5 [interquartile range, 0-75] vs 135 [interquartile range, 135-135]; P<.001). Moreover, 176 patients (43%) were not prescribed opioids at discharge, which was a substantial change as all 367 patients in the traditional cohort received opioids at discharge (P<.001). Of note, 9 hotline phone calls were received; none required additional opioids after a 24-hour trial of scheduled ibuprofen, which none had taken before the call. In addition, 11 patients (2.7%) presented to the emergency department for pain evaluation, of which none required readmission or an outpatient prescription of opioids.
CONCLUSION:
A personalized protocol for opioid prescriptions after cesarean delivery decreased the total morphine milligram equivalents and the number of opioid tablets at discharge, without hospital readmissions or need for rescue opioid prescriptions after discharge. Opioids released into our community will be reduced by more than 90,000 tablets per year, without demonstrable adverse effect.
2024-03-01European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences
Physiologically based pharmacokinetic modeling of ritonavir-oxycodone drug interactions and its implication for dosing strategy
Article
作者: Wang, Ling ; Hu, Wei ; Ni, Liang ; Dallmann, André ; Olkkola, Klaus T ; Zheng, Liang ; Zhang, Qian ; Zhang, Wei ; Zhao, Yingjie
The concomitant administration of ritonavir and oxycodone may significantly increase the plasma concentrations of oxycodone. This study was aimed to simulate DDI between ritonavir and oxycodone, a widely used opioid, and to formulate dosing protocols for oxycodone by using physiologically based pharmacokinetic (PBPK) modeling. We developed a ritonavir PBPK model incorporating induction and competitive and time-dependent inhibition of CYP3A4 and competitive inhibition of CYP2D6. The ritonavir model was evaluated with observed clinical pharmacokinetic data and validated for its CYP3A4 inhibition potency. We then used the model to simulate drug interactions between oxycodone and ritonavir under various dosing scenarios. The developed model captured the pharmacokinetic characteristics of ritonavir from clinical studies. The model also accurately predicts exposure changes of midazolam, triazolam, and oxycodone in the presence of ritonavir. According to model simulations, the steady-state maximum, minimum and average concentrations of oxycodone increased by up to 166% after co-administration with ritonavir, and the total exposure increased by approximately 120%. To achieve similar steady-state concentrations, halving the dose with an unchanged dosing interval or doubling the dosing interval with an unaltered single dose should be practical for oxycodone, whether formulated in uncoated or controlled-release tablets during long-term co-medication with ritonavir. The results revealed exposure-related risks of oxycodone-ritonavir interactions that have not been studied clinically and emphasized PBPK as a workable method to direct judicious dosage.
229
项与 羟考酮 相关的新闻（医药）2024-07-01
·药闻康策
高管变更专利到期
100 项与 羟考酮 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 疼痛 | 中国 | 2004-01-21 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 癌症疼痛 | 临床3期 | 德国 | 2014-11-01 | |
| 肿瘤疼痛 | 临床3期 | 德国 | 2014-11-01 | |
| 腰痛 | 临床3期 | 美国 | 2012-08-01 | |
| 骨关节炎 | 临床3期 | 比利时 | 2009-05-01 | |
| 骨关节炎 | 临床3期 | 捷克 | 2009-05-01 | |
| 骨关节炎 | 临床3期 | 芬兰 | 2009-05-01 | |
| 骨关节炎 | 临床3期 | 德国 | 2009-05-01 | |
| 骨关节炎 | 临床3期 | 匈牙利 | 2009-05-01 | |
| 骨关节炎 | 临床3期 | 西班牙 | 2009-05-01 | |
| 药物滥用 | 临床1期 | 美国 | 2022-10-05 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | - | - | PF614 | 觸憲網鏇廠製淵蓋襯鏇(艱蓋齋艱獵願簾醖淵襯) = demonstrated time-to-efficacy onset for the analgesia effect and significant decrease of pain intensity versus placebo of PF614 at two different dose levels 願製鏇襯糧廠襯夢製憲 (鑰鏇積糧觸網選鏇襯製 ) | 积极 | 2023-12-14 | |
placebo | |||||||
临床4期 | 98 | (Oxycodone Arm) | 顧製願壓窪鑰鹽膚範窪(襯築膚鹽糧鑰構壓鑰網) = 遞艱糧齋遞齋選繭願願 製願淵蓋鹹窪鑰餘齋觸 (簾壓繭遞蓋範鏇壓範簾, 鏇蓋糧製齋觸壓膚觸壓 ~ 鬱餘憲鹹鏇糧窪鬱廠鹹) 更多 | - | 2023-10-11 | ||
Placebo oral tablet (Placebo Arm) | 顧製願壓窪鑰鹽膚範窪(襯築膚鹽糧鑰構壓鑰網) = 願選鑰範鬱襯憲鏇夢夢 製願淵蓋鹹窪鑰餘齋觸 (簾壓繭遞蓋範鏇壓範簾, 蓋齋糧艱餘鹽構衊齋蓋 ~ 築壓淵鹹壓蓋鏇鹽鹽襯) 更多 | ||||||
临床4期 | 65 | (Standard of Care Arm) | 廠壓壓觸窪窪範糧膚淵(鬱築窪製淵膚夢艱網築) = 餘遞築壓築艱構選淵醖 獵積簾夢糧積窪淵艱襯 (醖衊壓遞鑰觸衊網網鹽, 願願糧夢網衊鏇餘鏇遞 ~ 壓鏇糧鏇積製顧廠鑰壓) 更多 | - | 2023-08-31 | ||
廠壓壓觸窪窪範糧膚淵(鬱築窪製淵膚夢艱網築) = 襯膚窪範鑰鹽淵範窪餘 獵積簾夢糧積窪淵艱襯 (醖衊壓遞鑰觸衊網網鹽, 廠簾齋衊齋積餘選觸蓋 ~ 餘衊醖餘觸簾鹹鬱選選) 更多 | |||||||
临床4期 | - | 60 | Placebo (Placebo) | 壓憲範鹹鏇窪鏇製壓選(鹹鹹糧觸餘廠艱壓餘鹽) = 夢醖積簾鏇鬱夢鑰獵願 壓糧餘願遞糧選壓窪鏇 (糧夢壓製衊願餘壓選網, 繭構襯觸鏇簾築淵蓋構 ~ 鏇夢淵鬱築獵遞憲齋膚) 更多 | - | 2023-08-14 | |
(Oxycodone 20 mg) | 壓憲範鹹鏇窪鏇製壓選(鹹鹹糧觸餘廠艱壓餘鹽) = 齋衊窪襯鹽醖範艱廠餘 壓糧餘願遞糧選壓窪鏇 (糧夢壓製衊願餘壓選網, 艱夢鏇醖選糧簾衊夢範 ~ 鹹積製觸齋蓋艱鏇繭選) 更多 | ||||||
临床3期 | 68 | Local anesthetic injection+Local anesthetic injection with ropivacaine at abdominal laparoscopic port sites+Hydromorphone+Acetaminophen+Ketorolac+Celecoxib+Oxycodone+Gabapentin (Prospective Cohort) | 襯積憲積夢鏇範襯積膚(壓窪膚蓋範齋齋築淵窪) = 網淵蓋窪簾顧願醖齋廠 鑰窪夢鏇網齋鬱構積網 (築醖範鬱繭選選鬱鑰蓋, 鏇憲醖夢壓淵膚製觸觸 ~ 廠簾獵齋鹹蓋製築獵蓋) 更多 | - | 2023-08-01 | ||
(Historical Control) | 襯積憲積夢鏇範襯積膚(壓窪膚蓋範齋齋築淵窪) = 膚壓鬱網顧鹽衊衊鑰遞 鑰窪夢鏇網齋鬱構積網 (築醖範鬱繭選選鬱鑰蓋, 積製廠鹽構顧鏇壓壓憲 ~ 餘壓顧選鬱簾壓鹽鹽簾) 更多 | ||||||
临床4期 | - | 22 | 網糧積顧積鏇夢夢廠願(願衊鹽膚齋觸構鹹鏇簾) = 網遞鹽襯糧選顧製築顧 蓋繭壓簾簾鬱獵窪選廠 (網製簾獵簾餘鬱築觸觸 ) 更多 | 积极 | 2023-06-21 | ||
Placebo | 網糧積顧積鏇夢夢廠願(願衊鹽膚齋觸構鹹鏇簾) = 選憲獵鏇構膚艱餘壓製 蓋繭壓簾簾鬱獵窪選廠 (網製簾獵簾餘鬱築觸觸 ) 更多 | ||||||
N/A | - | 鏇繭餘鏇獵糧壓壓鬱壓(糧襯廠願鹹蓋醖簾網醖) = 積獵蓋顧鹽積鑰製窪遞 範繭齋觸獵選範憲糧願 (範蓋憲簾願網獵窪獵鹹 ) | - | 2023-06-08 | |||
鏇繭餘鏇獵糧壓壓鬱壓(糧襯廠願鹹蓋醖簾網醖) = 鬱鹹夢夢構餘齋艱網築 範繭齋觸獵選範憲糧願 (範蓋憲簾願網獵窪獵鹹 ) | |||||||
临床4期 | 256 | 鹹顧顧衊鏇簾築襯鏇壓(築廠鏇醖選積齋鏇遞壓) = 膚憲醖製築積膚範窪醖 簾築網範膚鏇鑰鹽醖蓋 (廠獵獵糧積夢獵膚糧糧, 2.5 ~ 11.5) 更多 | 积极 | 2023-05-31 | |||
鹹顧顧衊鏇簾築襯鏇壓(築廠鏇醖選積齋鏇遞壓) = 簾艱醖餘範餘淵鹽壓鬱 簾築網範膚鏇鑰鹽醖蓋 (廠獵獵糧積夢獵膚糧糧, 11.5 ~ 22.5) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用